1. Market Research
  2. > Biotechnology Market Trends
  3. > Depression Partnering 2010-2015

Depression Partnering 2010-2015

  • May 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

Summary
The Depression Partnering 2010-2015 report provides understanding and access to the depression partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in depression partnering deals
Top depression deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The Depression Partnering 2010-2015 report provides understanding and access to the depression partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in depression partnering deals
Top depression deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Depression Partnering 2010-2015 provides understanding and access to the depression partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of depression partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors depression technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual depression deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of depression partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of depression technologies and products.

Report scope

Depression Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to depression trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in depression dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 50 depression deals
The leading depression deals by value since 2010

In Depression Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Depression Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of depression deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 50 actual depression deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Keywords

depression, psychiatry, partnering, licensing, deals, alliances, merger and acquisition, M&A, big pharma

Table Of Contents

Depression Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in depression partnering

2.1. Introduction
2.2. Depression partnering over the years
2.3. Depression partnering by deal type
2.4. Depression partnering industry sector
2.5. Depression partnering by stage of development
2.6. Depression partnering by technology type

Chapter 3 - Average deal terms for depression

3.1 Introduction
3.2 Average deal terms for depression
3.3 Depression headline values with median calculation
3.4 Depression upfront values with median calculation
3.5 Depression milestone values with median calculation
3.6 Depression royalty rates with median calculation

Chapter 4 - Active depression dealmakers

4.1. Introduction
4.2 Most active depression dealmakers
4.3. Top depression deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Depression dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Depression partnering since 2010
Figure 2: Depression dealmaking activity- 2010 to 2015
Figure 3: Depression partnering by deal type since 2010
Figure 4: Depression partnering by industry sector since 2010
Figure 5: Depression partnering by stage of development since 2010
Figure 6: Depression partnering by technology type since 2010
Figure 7: Depression deals with a headline value
Figure 8: Depression deals with upfront payment values
Figure 9: Depression deals with milestone payments
Figure 10: Depression deals with royalty rates, %
Figure 11: Top depression deals by value since 2010
Figure 12: Big pharma - top 50 - depression deals 2010 to 2015
Figure 13: Big pharma depression deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - depression deals 2010 to 2015
Figure 15: Big biotech depression deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

Cancer Diagnostics: A Market on the Verge of Explosion--Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence

  • $ 15900
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $24,500.  DataPack (test volumes, sales forecasts, supplier shares) $15,900. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the global cance ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.